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DyeCycleViolet was used to set up the side population (SP)
functional assay aimed at identifying subpopulations of malignant
pleural mesothelioma (MPM) tumor cells with chemoresistance phe-
notype associated with ABCG2 transporter activity. Self-renewal,
chemoresistance and tumorigenicity were tested for SP and non-side
population (NSP) cells. Tumors were characterized by mesothelin,
calretinin, N-cadherin, D2-40 and Wilms tumor 1 (WT1) immuno-
histochemistry. Surface expression of mesenchymal stem cell
markers CD90, CD73 and CD105 was investigated in SP and NSP
cells. We identified SP cells with self-renewal properties and in-
creased chemoresistance in MPM cell lines and tumor-derived
primary cell cultures. Compared with the non-SP fraction (NSP),
the SP fraction led to the development of tumors including cells with
mesothelium precursor phenotype characterized by mesenchymal
morphology, being WT1 negative but cytoplasmic D2-40 positive
and having a tendency of increased tumorigenicity. The same
phenotypic shift was observed in patients with relapsing tumors
after chemotherapy. Furthermore, the SP cells were enriched in
CD1052/low expressing cells, which were small sized and had in-
creased tumorigenicity compared with CD105high cells. Taken to-
gether, our results support the hypothesis that MPM CD1052/low,
chemoresistant small sized SP cells may constitute the cellular pool
out of which recurrence develops. Further characterization of mech-
anisms of chemoresistance and self-renewal should lead to targets
specific for this subpopulation in MPM patients.
Introduction
Asbestos-related malignant pleural mesothelioma (MPM) is expected
to peak in 2020 (1). Survival rates are still 1 year (depending on the
age and treatment) after diagnosis (2). Objective chemotherapy re-
sponse is achieved in ,50% of patients and has limited duration (3).
In order to gather a better understanding of MPM biology, which
may ultimately help defining better therapeutic strategies, we consid-
ered parallel aspects between MPM development and other tumors
linked to chronic injury (4). The asbestos fibers-induced MPM
development is due to accumulation of inhaled asbestos fibers in the
pleural space and subsequent damage of the mesothelium (5). Chronic
tissue repair follows activating stem cell signaling pathways to
regenerate the tissue but, because of persistent system stimulation,
oncogenic events occur leading to tumor formation (reviewed in ref.
6). The presence within the latter of a population of cancer stem cells
(CSC) highly resistant to chemotherapy might be the cause of tumor
recurrence. Hence, the aim of our study was originally to identify and
characterize MPM CSC. The latter, which have the capability to
create exact tumor phenocopies when transplanted from one mice
to the next, have been proposed to exist (7) based on the pioneer work
identifying leukemic stem cells as CD34þ/CD38 cells, like hemato-
poietic stem cells (HSCs) in human acute myeloid leukemia (8,9). The
presence of CSCs in solid tumors was identified for the first time as
a small subset of heterogeneous breast cancer cells which were
phenotypically distinct and characterized as CD44þ/CD24/low (10).
Since then, for many solid tumors, CSCs have been identified using
corresponding tissue stem cell surface markers (reviewed in ref. 11).
Normal mesothelium stem cell surface markers are not yet available
to identify potential MPM CSCs. Hence, we used a functional assay,
which identifies a small and distinct subset of cells called ‘side
population’ (SP), with phenotypic markers of multipotential HSC
after staining bone marrow with the DNA staining dye Hoechst
33342 (12). The SP is due to the expression of functional adenosine
triphosphate-binding cassette (ABC) transporters (13). When living
cells are stained with Hoechst 33342, SP cells do efflux the DNA-
staining dye via their ABC transporters. When cells are coincubated
with ABC transporter inhibitors verapamil or fumitremorgin C,
Hoechst 33342 is no longer effluxed leading to a shift in the dual
emission wavelength fluorescence-activated cell sorting (FACS)
analysis upon which the SP can be identified. The ABCG2 drug trans-
porter is responsible for the SP in the bone marrow (13,14). Although
this assay has already been applied to mesothelioma cell lines (15),
several issues are still needed to be addressed. Firstly, self-renewal of
sorted SP has not been investigated yet, second tumorigenicity has
been determined only for SP and NSP cells sorted from MS-1 cell
line, which has a biphasic histotype and no differences were found. In
our study, those questions were addressed using primary cultures from
xenografts, either from a cell line or from a patient-derived tumor
instead of cell lines. In addition, surface phenotype and chemoresist-
ance were characterized.
Material and methods
Tissue samples
Human tumor specimens were obtained and processed as described previously
(16,17).
Cell lines and primary cell cultures
The human promyelocytic leukemia cell line HL60/Dox selected by chronic
exposure to doxorubicin was kindly provided by Dr M.Andreev (Department
of Blood and Marrow Transplantation, UT MD Anderson Cancer Center,
Huston, TX) and maintained in RPMI 1640 (Sigma–Aldrich, Buchs SG,
Switzerland) supplemented with 10% fetal calf serum (FCS) (Omnilab, Mett-
menstetten, Switzerland), 1% penicillin/streptomycin and 1 mM L-Glutamine
(both obtained from GIBCO, Basel, Switzerland). The breast cancer cell line
MCF-7 was maintained in RPMI 1640 supplemented with 10% FCS, 1%
penicillin/streptomycin and 2 mM L-Glutamine. Primary MPM cell cultures
were established from surgical specimens or xenografts as follows: tumors
were blended into small pieces of 1–3 mm2, then fragments were directly
added to culture medium adapted from Connell et al. (18) (Dulbecco’s
modified Eagle’s medium/F12 þ GlutaMax (GIBCO), 15% FCS, 0.4 lg/ml
hydrocortisone (Sigma–Aldrich), 10 ng/ml epidermal growth factor (GIBCO),
1% ITS (insuline, transferrin, selenium; GIBCO), 1 mM sodium pyruvate
(Sigma–Aldrich), 100 lM beta-mercaptoethanol (Fluka, Buchs SG, Switzer-
land), supplemented with 1% non-essential amino acids (GIBCO) and 30%
conditioned medium) or were incubated with collagenase 3 (200 U/ml; Wor-
thington Biochemical Corporation, Lakewood, NJ) and hyaluronidase (100 U/
ml) for 6 h at 37 C followed by digestion with 0.25% Trypsin/ethylenediami-
netetraacetic acid (EDTA; GIBCO) for 2 min at 37C and with 20 mg/ml
DNAseI (Worthington Biochemical Corporation) for additional 2 min at
37C. At the end of the collagenase digestion, tissues were filtered through
a 70 lm cell sieve. The filtrate was centrifuged and the pellet resuspended in
culture medium. The mesothelioma cell lines ZL34 and ZL55 were established
in our laboratory (19). The MPM cell line H28 and Met5A, a mesothelial cell
line obtained by SV40 transformation of mesothelial cells (20), were obtained
Abbreviations: ABC, adenosine triphosphate-binding cassette; CSC, cancer
stem cell; DCV, DyeCycleViolet; EDTA, ethylenediaminetetraacetic acid;
FACS, fluorescence-activated cell sorting; FCS, fetal calf serum; HSC, hema-
topoietic stem cell; MPM, malignant pleural mesothelioma; SP, side popula-
tion; NSP, non-side population; PBS, phosphate-buffered saline.
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from ATCC. All cell lines used in this study were authenticated by DNA fin-
gerprinting (Microsynth, Balgach, Switzerland).
Gene expression analysis
Selected gene expression analysis was performed as described previously
(16,17). Additional primers are listed in the Supplementary Table I, available
at Carcinogenesis Online. The heatmap was produced with R using default
options on DCt raw data. We used the logarithmic expression values and
subtracted for each gene its mean expression.
Measurement of cell growth
To test sensitivity to mitoxantrone, cells were first incubated for 1 h with mitox-
antrone (Sigma–Aldrich) (1 ng/ml) then verapamil (20 lM) was added or not for
1 h. Both drugs were suspended in medium without serum. After incubation,
drugs were removed and cells were grown for further 3 days in serum containing
medium. Sensitivity to cisplatin (0–16 lM) was tested in MPM medium con-
taining 0.5% FCS. Cell growth was determined as described previously (21).
Western blot analysis
Western blotting was done as described (16). The western blots are represen-
tatives of two to five independent experiments.
SP analysis
Cells were stained with DyeCycleViolet (DCV) using a method described
previously (22–24) and adapted as follows. Briefly, cells were washed
with phosphate-buffered saline (PBS), trypsinized and resuspended in Dulbec-
co’s modified Eagle’s medium:F12 supplemented with 2% FCS, 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma–Aldrich),
0.4 lg/ml hydrocortisone, 10 ng/ml epidermal growth factor, 1% ITS, 100 lM
b-mercaptoethanol, 1 mM sodium pyruvate, 2 mM L-Glutamin and 1% non-
essential amino acids. As positive controls, HL60/Dox cells were used. Cells
were incubated with DCV (0.5 lM; Invitrogen, Basel, Switzerland) in the ab-
sence or presence of verapamil (50 lM; Sigma–Aldrich) at 37C for 90 min in
the dark mixing every 15 min. Then, cells were spin down at 4C and resus-
pended in ice-cold Hanks’ balanced salt solution (HBSS; GIBCO) supplemented
with 10 mM HEPES and 5 mM EDTA (Amresco). Viable cells were gated with
propidium iodide (PI; 2 lg/ml). Cells were gated on the FACSAria (Becton
Dickinson, Allschwil, Switzerland) Forward Scatter Channel and Side Scatter
Channel, a live gate was placed on cells excluding propidium iodide (Excitation
488 nm, Emission 610/20 nm) and single cells were gated based on Forward
Scatter Channel (Forward Scatter Channel line versus pulse width) and Side
Scatter Channel (Side Scatter Channel line versus pulse width). SP was deter-
mined by a gate placed on 450/40 versus 530/30 nm emission dot plot on
a logarithmic amplified fluorescence scale after DCV excitation at 407 nm
(25). The SP gate was identified using verapamil which blocks drug efflux. These
settings gave the same results as 450/40 versus 650 nm longpass and allowed
a direct comparison with results on surface phenotyping using the CyAn ADP
analyzer (Beckman Coulter, Nyon, Switzerland), described below where only
the 530/40 nm filter for 405 nm excitation was available. After sorting, cells were
cultured or processed for mice xenografts.
Immunohistochemistry
De-paraffinized sections were subjected to antigen retrieval using Tris/EDTA
(1 mM/0.1 mM, pH9) or pepsin digestion (for WT1). Following quenching in
0.3% H2O2 (20 min) and permeabilization in 0.05% Saponin (5 min; Fluka),
blocking was performed in 2% bovine serum albumin in PBS with 1% horse
serum (20 min; Vector Laboratories) at room temperature. Sections were in-
cubated with primary antibodies (in supplementary figures: N-cadherin 6G11,
1:50; DAKOCytomation, Baar, Switzerland; mesothelin 5B2, 1:30; NovoCas-
traTM Laboratories and calretinin 1:50, Abcam, Cambridge, UK) overnight at
4C. Negative controls were incubated with secondary biotinylated antibody
only (Vectastain Elite ABC Kit; Vector Laboratories, Servion, Switzerland).
Sections were washed with PBS and incubated with secondary biotinylated
antibody for 45 min at room temperature. Staining was visualized using 3,3#-
diaminobenzidine tetrahydrochloride (Sigma–Aldrich), counterstained with
VectorHematoxilyn QS (Vector Laboratories) and analyzed either using a Leica
DM IRBE microscope and image acquisition with Nikon Coolpix and Retiga
Cooled Color 12-bit camera and QCapture (QImaging) or using a Zeiss Mirax
Midi Slide Scanner and image acquisition with a 3 CCD color camera and Mirax
Viewer (Zeiss, Feldbach, Switzerland). A minimum of 200 cells was evaluated.
Surface phenotyping
Cells resuspended in ice-cold PBS/2 mM EDTA were incubated with anti-
bodies against CD105 (SN6, allophycocyanin labeled; eBioscience, Vienna,
Austria), CD90 and CD73 (5E10 and AD2, respectively, both phycoerythrin
labeled; BD Bioscience, Allschwil, Switzerland) and podoplanin (purified,
kindly provided by Dr D.Kerjaschki, Clinical Institute for Pathology, Medical
University of Vienna, Vienna, Austria) and with allophycocyanin labeled,
phycoerythrin labeled and purified IgG controls (eBioscience and BD Biosci-
ence, respectively) at 4C for 30 min in the dark. Secondary antibody (phyco-
erythrin labeled; Dianova, Rheinfelden, Switzerland) for podoplanin analysis
was incubated at 4C for 30 min in the dark. After washing with PBS cells were
resuspended in ice-cold PBS/2 mM EDTA and analyzed. CD105/low and
CD105high cells were identified and electronically gated on either the FACSA-
ria cell sorter or the CyAn ADP analyzer (Beckman Coulter) after allophyco-
cyanin excitation at 633 nm. The purity of sorted cells was verified directly
after sorting and was .98%.
Where additionally SP was investigated, cells were treated for the SP anal-
ysis prior to antibody incubation.
The expression of ABCG2 on the cell surface was verified by FACS analysis
as described (26).
MPM xenografts into NOD/SCID mice
NOD/SCID mice were bred and maintained under conditions approved by the
Animal Care Committee. Sorted cells were resuspended in Matrigel (Matrigel
Basement Membrane Matrix; Becton Dickinson) and injected under the renal
capsula of 6–8 weeks old mice that were irradiated with one Gray 1 day before
injection (27). Tumor tissues obtained from patients were directly implanted
under the renal capsula. The mice were anesthetized with isoflurane while cells
were injected. All animals were killed between 13 and 21 weeks posttrans-
plantation. Tumor volume in cubic centimeters was determined using the for-
mula (length  width2)/2, where length was the longest axis and width being
the measurement at right angles to the length.
Results
Identification and characterization of a SP in the MMPM cell line ZL55
In preliminary experiments, we established an SP protocol using as an
experimental control (28) the leukemia cell line HL60/Dox, which
over expresses multidrug resistance proteins, allowing the cells to
efflux the DNA staining dyes Hoechst 33342 or DCV. We observed
that using DCV, which has the advantage of being excited at non-UV
wavelength with an enhanced emission signal compared with Hoechst
33342 (23) resulted in a better separation of SP/NSP (Supplementary
Figure 1A is available at Carcinogenesis Online). In addition,
we found that DCV could be used at a concentration (0.5 lM) not
toxic to cells (supplementary Figure 2 is available at Carcinogenesis
Online), allowing to take into account the cytotoxicity concerns about
this method (29). This DCV protocol was first applied to breast cancer
cell line MCF-7 (30) to provide an additional control for low abun-
dance SP (supplementary Figure 1B available at Carcinogenesis on-
line and Table I).
Using the DCV protocol for the MPM cell line ZL55 (gating strat-
egy presented in supplementary Figure 3, available at Carcinogenesis
Online), we identified an SP of 2.1 ± 1.9% (n 5 31, mean ± SD,
Figure 1A and Table I), which was decreased by the drug transporter
inhibitor verapamil, indicating that these cells represented the SP
cells. To examine whether SP cells could regenerate SP and NSP cells,
ZL55 cells were sorted into SP and NSP and further cultured in vitro.
Reanalysis of ZL55 SP and NSP in respect to their SP/NSP distribu-
tion revealed that ZL55 SP was able to regenerate an SP (2.25%,
n 5 2), whereas only NSP (n 5 2) was obtained with ZL55 NSP.
These data suggest that an SP with self-renewal properties is present
in MPM ZL55 cells. In addition, the ZL55 SP was enriched with cells
expressing the drug transporter ABCG2 at both protein and messenger
RNA level (Figure 1B). To further characterize SP versus NSP derived
populations, the expression of N-cadherin and mesothelin, which we
routinely use to characterize our primary cultures (16), were investi-
gated. Both N-cadherin and mesothelin (Figure 1C, left panel) were
not detected in ZL55 SP cells in which a higher relative expression of
Sox2 was observed (Figure 1D). This might indicate that ZL55 SP
cells are in a less differentiated state. The relative expression of
MDR1 was also increased in the SP fraction (Figure 1D), which is
not surprising given the fact that DCV is a substrate of various ABC
transporters. Relative expression enrichment was also observed for
ABCC3 but not for ABCC1. All in all, these data indicate that an SP
with stem/progenitor cell properties is present in ZL55 cells.
Mesothelioma epithelial–mesenchymal transition
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Characterization of SP in additional MPM cell lines, MPM primary
cell cultures and in a primary mesothelial cell culture
Beside the mesothelioma cell line ZL55, we investigated the SP dis-
tribution in two additional MPM cell lines ZL34 and H28, in three
primary MPM cell cultures SDM96, SDM100 and SDM138, in a xe-
nograft derived primary MPM cell culture SDM103T2 (Figure 1A)
and in a primary mesothelial cell culture SDM104. In all these cell
lines and primary cell cultures, an SP was identified (Table I).
The fact that an SP is also present in the primary mesothelial cell
culture SDM104 indicates that a fraction of cells with potential self-
renewal capacity is present in cultured normal mesothelium.
SDM103T2 cells were selected for further characterization for two
reasons: firstly, they were derived from xenograft implantation of
a tumor after chemotherapy, offering the opportunity to detect
chemotherapy resistant cells. Secondly, tissue of relapsed tumor from
the same patient was also available for further comparison. As for
ZL55 cells, the SDM103T2 SP (Figure 1B, right panel) showed in-
creased expression of ABCG2 and was able to regenerate a next SP
(2.25%, n 5 1) when cultured. The latter (SDM103T2 SP1 SP1,
Figure 1B) was even further enriched for ABCG2 expression com-
pared with the remaining NSP (SDM103T2 SP1 NSP1). Similarly to
ZL55 cells, the expression of the MPM marker mesothelin was lower
in SP compared with NSP (Figure 1C, right panel) while this trend
was not observed for N-cadherin. Thus, it seems that SP phenotype
is accompanied by decreased expression of mesothelin, which is gen-
erally abundantly expressed in epithelioid MPM (31). No specific
enrichment of other ABC transporters in the SP fraction was observed
(data not shown).
SP cells tend to be more tumorigenic than NSP cells
To test whether the tumorigenicity of SP and NSP differs, various
numbers (102–105) of sorted ZL55 cells were injected under the renal
capsule of NOD/SCID mice and monitored for tumor development.
Both ZL55 SP and NSP gave rise to tumors when 105 cells were
implanted (n 5 4). By decreasing the injected cell number ,103,
neither ZL55 SP nor NSP gave rise to tumors (n 5 2). Injecting
between 103 and 104 cells of ZL55, SP and NSP led to tumor de-
velopment for both SP and NSP in three of four mice tested. Therefore,
similar to another study (15), no difference in a cell line SP versus NSP
tumorigenicity was observed. We then injected sorted SP and NSP
cells derived from an SP (ZL55 SPT) and an NSP (ZL55 NSPT3-3)
tumor. Both cell cultures gave rise to an SP fraction (0.9 ± 0.7% and
0.2 ± 0.1%, n 5 8 and n 5 3, respectively). By injecting between 103
and 104 of these tumors#-derived sorted cells, there was a tendency
(Figure 2A) to observe tumor formation more frequently with the SP
Table I. Average SP abundance
Cell line Average
SP (%)
Number of
replicates
Breast cancera MCF-7 2.3 ± 0.5 5
MPM ZL55 2.1 ± 1.9 31
ZL34 0.4 ± 0.1 3
H28 0.7 ± 0.3 4
Primary MPM SDM96 1.1 2
SDM100 1.1 2
SDM103T2 1.6 ± 1.5 24
SDM138 0.2 ± 0.2 3
Primary mesothelial cells SDM104 2.8 2
aUsed as control (28).
Fig. 1. ABCG2 and mesothelioma markers expression in the SP of an MPM cell line and a primary MPM xenograft cell culture (A) MPM cell line ZL55 and
xenograft SDM103T2 cells were stained with DCV (0.5 lM) in the absence () or presence (þ) of verapamil (50 lM). The SP (green gate) was defined as the
population decreasing by the addition of verapamil. (B) Western blot and real-time polymerase chain reaction (PCR) analysis to assess ABCG2 expression levels
in sorted SP and NSP cells. ABCG2 protein (BXP-21, 1:1000, Alexis Biochemicals, Lausen, Switzerland) was elevated in both ZL55 and SDM103T2 SP cells
compared with NSP and parental cells. ABCG2 messenger RNA was also enriched in ZL55 SP cells. (C) Western blot analysis to determine the expression of
mesothelin (MN-1, 1:1000; Rockland, Gilbertsville, PA) and N-cadherin (32/N, 1:2500; BD Bioscience) mesothelioma markers. Met5A cells were used as positive
control for these two mesothelioma differentiation markers. Mesothelin was decreased in exponentially growing sorted SP cells. N-cadherin was also decreased
but only in ZL55 SP cells. (D) Real-time PCR analysis revealed higher MDR1, ABCC3 and Sox2 messenger RNA expression in ZL55 SP compared with NSP
cells. Real-time PCR data were normalized to histones and expressed as mean ± SD (n5 3). Actin (C4, 1:10 000; ICN) was used as western blot loading control.
C.Frei et al.
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Fig. 2. Different phenotypes in freshly sorted SP/NSP and their derived tumors (A) SP from xenograft-derived tumors were enriched for tumor forming capacity in
NOD/SCID mice. About 103–104 cells were implanted under the renal capsula of 1 Gy-irradiated mice. (B) Unsupervised clustering of SP- and NSP-derived tumors.
Analyzed genes include ABC transporters ABCG2, MDR1 and ABCC1; stem cell markers Sox2, nestin, OCT4A, Bmi-1 and CD90; sonic hedgehog activity markers
Gli-1, Patch1; hypoxia-controlled CAIX and Wisp2 and matrix-remodeling Slug, Twist and PAI-1. Matrix of relative gene expression values is shown as heatmap. Red
indicates downregulated genes, blue indicates upregulated genes. (C and D) Representative tumors stained with either hematoxylin and eosin (H&E), without primary
antibody (control) or with antibodies against WT1 (6F-H2, 1:50; DAKOCytomation) or podoplanin (D2-40, 1:50; DAKOCytomation). WT1 expression decreased in
SP-derived tumor tissues, whereas podoplanin shifted from the membrane to the cytosol compared with NSP-derived tumor tissues for ZL55 cells and SDM103T2
tumor. In ZL55 SPT SPT2 (H&E), arrow denotes spindeloid tumor moiety, whereas arrowhead represents epitheloid mesothelioma (E) Tumor relapsing in patient
SDM103 shifts toward mesothelium precursor phenotype defined as the absence of WT1 expression, increased podoplanin cytosolic staining and spindeloid
phenotype. The scale bar represents 20 lm except for WT1 in SDM103T2 and SDM103T2 SPT2 (12.5 lm).
Mesothelioma epithelial–mesenchymal transition
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fraction. For the xenografted tumor-derived SDM103T2 only, SP cells
gave rise to tumors. All in all, there is a tendency (P5 0.12, two-tailed
chi-square test) for the SP fraction to have higher tumor initiating
ability (8/14) compared with NSP fraction (4/14).
The existence of intrinsic differences between SP- and NSP-
sorted cells was supported by colony-forming efficiency assay. Plat-
ing ZL55 SPT, SP and NSP cells resulted in the growth of two colony
types: compact and loose (supplementary Figure 4 is available at
Carcinogenesis Online). The yield of loose colonies was signifi-
cantly (P , 0.01, Mann–Whitney test) higher in ZL55 SPT NSP
compared with SP cells. SDM103T2 could not be analyzed in a sim-
ilar way because cells grow spreading in the dish. However, a similar
observation was obtained in ZL34 cells.
SP-derived tumors shift their expression toward mesothelium precursor
phenotype
In order to get further insight into the mechanism of increased tumor-
igenic potential of SP-derived cells, gene expression and immunos-
taining was performed on SP- and NSP-derived tumors. The relative
expression of mesothelioma markers calretinin (32), podoplanin (33)
and mesothelin (31); ABC transporters ABCG2, MDR1 and ABCC1;
stem cell markers Sox2, nestin, OCT4A, Bmi-1, CD90; sonic hedgehog
activity markers Gli-1, Patch1; hypoxia controlled CAIX and Wisp2 and
matrix-remodeling Slug, Twist and PAI-1 were investigated in 10 ZL55
SP- and NSP-derived tumors. Some mouse genes (Gli-1, Patch1 and
Sca-1) were also included to take into account the mouse stromal com-
ponents. Although of all the genes analyzed, only Patch1 was signifi-
cantly enriched in SP-derived tumors (P , 0.05, two way analysis of
variance), it nevertheless indicates that SP- and NSP-derived tumors are
different and suggests the involvement of sonic hedgehog signaling. An
unsupervised clustering showed separation of SP and NSP tumors (Fig-
ure 2B) with the exception of three tumors. In addition to Patch1, the
expression of podoplanin was enriched in SP compared with NSP de-
rived tumors. Latter observation was confirmed by immunostaining of
tumor sections (Figure 2C and D and Table II) where we observed that
podoplanin staining shifted from the membrane to the cytoplasm in SP
derived tumors.
Mesothelioma is classified according to histopathology into epitheli-
oid, biphasic and sarcomatoid subtype, with the biphasic type being
defined as a tumor comprising.10% of both epithelioid and sarcoma-
toid areas (34). In SP-derived tumors, we observed a morphological
shift from 100% epithelioid tumor to a mixed morphology for
ZL55-derived tumors or to an increased spindeloid phenotype for
SDM103T2 cells (Table II). The latter was paralleled by a significant
decrease (P , 0.01) in cells with positive nuclear WT1 immunostain-
ing (30 and 98% in ZL55- and SDM103T2-derived tumors, respec-
tively). In contrast to observations in vitro where differences in
mesothelin and N-cadherin expression were observed in SP and NSP
fractions, all tumoral cells showed positive immunostaining for these
markers (supplementary Figure 5 is available at Carcinogenesis
Online). There can be many reasons for it, including growth in an in
vivo environment. In addition, all tumors were positive for calretinin.
The resistance of stem-like cells to conventional chemotherapy is
thought to be the cause of tumor recurrence. Hence, we investigated
whether the recurrence tumor SDM141 from the patient SDM103,
from which SDM103T2 were derived, would have a similar shift
toward mesothelium precursor phenotype, defined here as the absence
of WT1 expression, podoplanin shift from membrane to the cytosol
and spindeloid phenotype. We observed indeed a loss of WT1 expres-
sion, an increased cytosolic podoplanin immunostaining and a shift
toward sarcomatoid morphology in SDM141 sample compared with
epithelioid SDM103 phenotype (Figure 2E). These observations in-
dicate first that in the xenograft (SDM103T2) grown in mice, cells
selected to grow were already shifting to spindeloid phenotype com-
pared with parental tumor and second that xenografted SP cells be-
have like relapsing tumors, buttressing the hypothesis that relapse
might be due to resistant cancer stem-like cells. Similar results were
observed for tumor evolution in other two patients (supplementary
Figure 6 is available at Carcinogenesis Online).
ZL55 SPT cells were more chemoresistant to chemotherapeutics
Since mesothelioma patients develop resistance against chemotherapy
and because ABCG2 expression is correlated with a higher resistance to
chemotherapeutics, we investigated the chemoresistance of ZL55 SPT
and ZL55 NSPT3-3 cells. The latter were incubated either with verap-
amil, with mitoxantrone, a known ABCG2 substrate, or with a combi-
nation of verapamil and mitoxantrone (Figure 3A). ZL55 SPT cells were
more resistant to mitoxantrone compared with ZL55 NSPT3-3 cells, but
this difference was abolished (P, 0.01, paired t-test) in the presence of
verapamil. Additionally, ZL55 SPT, and ZL55 NSPT3-3 cells were in-
cubated with different concentrations of cisplatin, a chemotherapeutic
agent commonly used for the treatment of mesothelioma patients. Also
in this case, ZL55 SPT cells were significantly (P, 0.001, t-test) more
resistant to a high concentration of cisplatin compared with ZL55
NSPT3-3 cells (Figure 3B). Cisplatin induced DNA damage was similar
in both ZL55 SPT and NSPT3-3 cells as indicated by the phosphoryla-
tion of the histone variant H2AX (Figure 3C), occurring downstream
DNA damage response (reviewed in ref. 35). However, a better survival
in ZL55 SPT compared with NSPT3-3 cells was correlated with higher
basal expression of survivin (Figure 3C), an antiapototic protein upre-
gulated in MPM (36). In addition, cisplatin exposure resulted in a further
increase of survivin levels, which contributes to chemoresistance, as we
have described previously (37). All in all, these data indicate that SP
derived cells are more chemoresistant.
SP cells are CD105/low
To gather more information on the SP phenotype, we determined
whether mesenchymal stem cell (MSC) markers CD105, CD90 and
CD73, which were expressed in all MPM investigated (Supplemen-
tary Table II is available at Carcinogenesis Online), would be differ-
entially expressed in the SP itself. We also investigated the expression
of podoplanin and of ABCG2, which were differentially expressed in
the various cultures. The SP was specifically enriched in CD105/low
cells for SDM103T2 (4.9 ± 2.8-fold enrichment, P , 0.05, Mann–
Whitney test, n 5 4) (Figure 4A). Similar results were obtained for
ZL55 cells. In addition, CD105/low cells were smaller (Figure 4B).
No specific enrichment was observed with the other two markers.
Sorted ZL55 CD105/low cells induced tumors which were five times
larger (P , 0.02, n 5 4, t-test) compared with CD105high cells
buttressing the existence of a cell subpopulation with high tumori-
genic potential (Figure 4C). Consistent with this observation, Ki67
proliferation marker immunostaining was more abundant in ZL55
CD105/low cells-derived tumors (Figure 4D).
Table II. Spindeloid cells and higher cytoplasmic podoplanin expression in
ZL55 SP and SDM103T2 SP-derived tumors compared with contra laterally
derived NSP tumors or parental cells
Morphology Podoplanin
Epithelioid Spindeloid Positive cells (%) Mb Cyt
Mouse 1
ZL55 SPT3-3 90% 5–10% 5 þ þþ
ZL55 NSPT3-3 100% 0% 2–5 þþ þ
Mouse 2
ZL55 SPT SPT2 95% 5% 30 þþ þþ
ZL55 SPT NSPT 100% 0% 10 þþ þ
Mouse 3
ZL55 SPT SPT3 95% 5% 80 þ þþ
ZL55 SPT NSPT2 100% 0% 30–40 þþ þ
SDM103T2 20 80 50 þþ þ
SDM103T2 SPT 10 90 10 þ þþþ
SDM103T2 SPT2 0 100 50 þ þþþ
Mb, membrane; Cyt, cytoplasmic.
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Discussion
In this study, we identified an SP with self-renewal and chemoresistance
capacity, enriched in CD105/low cells and able to induce, when im-
planted under the renal capsule of NOD/SCID mice, the growth of a tu-
mor with increased spindeloid morphology. Furthermore, we observed
that CD105/low cells develop larger tumors compared with CD105high
cells. Unfortunately, the yield of SP in CD105/low cells was insufficient
to allow any investigation of the double selection. However, based on
current knowledge on embryonic mesothelium development, the pro-
posed recruitment of adult precursor cells by asbestos (38) and on our
own results, we put forward the hypothesis that MPM SP CD105/low
cells include mesothelioma cells responsible for tumor recurrence in
patients (supplementary Figure 7 is available at Carcinogenesis Online).
MPM SP fractions varied between cell cultures but were in the same
range of magnitude as found in other cancer types (39). They were
enriched for ABCG2 transporter expression as observed by others
(28,40) and the fraction of ABCG2 surface-positive cells was in a similar
range as the SP fraction. In addition, the ABCG2-specific inhibitor fu-
mitremorgin C (41) inhibited dye efflux (data not shown), therefore, it is
likely that ABCG2 is responsible for the SP phenotype in MPM.
The epithelioid differentiation marker mesothelin was low in the
SP fraction. Not much is known about the regulation of mesothelin
expression. However, in MexTag mice in which the SV40 T-antigen
(Tag) is under the control of the mesothelin promoter and which
develop MPM tumors upon exposure to asbestos fibers, Tag is not
detected in the unexposed mice (42). This may indicate that the cells
that are stimulated to proliferate upon asbestos fibers exposure are
undifferentiated precursor cells. The latter have been recently described
in normal mesothelial primary cultures (43).
Similar to another study using MS-1 MPM cell line (15), no differ-
ence in tumorigenicity of SP versus NSP was observed, when starting
material was a cell line. Nevertheless, tumors from xenograft-derived
SP had a tendency to be more frequent but most importantly shifted
toward a precursor phenotype defined here as enriched for podoplanin
expression and low WT1 expression. It is noteworthy that podoplanin,
also called D2-40 antigen, is a marker of splanchnic mesoderm (44)
from where mesothelium derives. Hence, SP-derived tumors have an
increased expression of mesothelium precursor marker. WT1 is a tran-
scription factor expressed at the time of switch from mesenchymal to
epithelial cells in mesothelium precursor cells (45). Continuous WT1
expression is conserved in mesothelium through adult life and is main-
tained in mesothelioma (46). However, it decreases during epithelial to
mesenchymal transition occurring for example in sarcomatoid meso-
thelioma (47). Altogether, these data indicate that SP-derived tumors
shift their expression toward mesothelium precursor phenotype.
Consistent with a mesenchymal–epithelial transition concept and
precursors being of mesenchymal phenotype, SP-derived tumors
shifted backwards from epithelioid to spindeloid morphology charac-
terized by cytoplasmic podoplanin expression as observed by others
(33,48–50) and decrease of nuclear WT1 staining (47).
This phenotype shift cannot be attributed to the microenvironment
since such changes were not observed in NSP cells-derived tumors
developed contra laterally. In addition, the increase in mesenchymal
profile was consistent with the hypothesis that mesothelium injury,
due to asbestos fibers accumulation in the pleural space, activates
tissue repair involving MSC (38). It is possible, as suggested by
Beachy et al.(4), that persistent injury and stimulation of repair would
lead in such cells to oncogenic events, represented in our model by the
loss of NF2 and INK4A function (reviewed in ref. 51).
Furthermore, we investigated MSC markers CD105, CD90 and
CD73 expression in MPM cell lines and primary cell cultures. All
investigated MPM cell lines and primary cell cultures were positive
for all three MSC markers but only CD105 was differently expressed
in SP and NSP: SP was enriched in CD105/low cells. The latter de-
veloped larger tumors compared with CD105high cells. CD105 is an
ancillary-transforming growth factor b receptor, and it is not clear
whether its differential expression in MPM cells is responsible for
the observed phenotype. In HSCs, CD105-positive cells contain all
the long-term repopulating HSC activity within bone marrow SP (52),
whereas others have suggested a function of CD105 as a tumor
suppressor in epithelial cancer (53). Hence, functional studies are
necessary to address any role of CD105 in MPM tumorigenicity.
Intriguingly, CD105/low cells had also a smaller size. This is in line
with observation from Grichnik et al. who identified SP cells in met-
astatic melanoma cell lines which, compared with NSP cells, were
small in size and gave rise to a heterogeneous cell population (54). A
small size for stem-like cells has also been reported in glioma cells
(30) and in squamous cell carcinoma (A431) cells (55).
Alternatively to the hypothesis that asbestos fibers recruit and alter
a mesothelium precursor, acquisition of oncogenic lesions may occur
in terminally differentiated cells resulting in dedifferentiation to
a primitive stem-like state. This state is often associated with
Fig. 3. SP-derived tumor cells are more chemoresistant (A and B) ZL55 SPT
and NSPT3-3 cells were plated in 96-well plates and treated 24 h later with
verapamil (50 lM), mitoxantrone (1 ng/ml) and a combination of the two for
1 h or with different cisplatin concentrations for 72 h. The MTT assay was
performed 72 h after beginning of the drug treatment. ZL55 SPT-derived
cells were more (P , 0.01) chemoresistant to mitoxantrone compared with
NSPT3-3-derived cells and this difference was abolished by verapamil. ZL55
SPT cells were also more (P , 0.001) resistant against high doses of
cisplatin. The data were normalized to the drug-untreated control. (C)
Western blot analysis to assess the expression of the DNA damage sensing
protein cH2AX biomarker (JBW301, 1:1000; Millipore, Zug, Switzerland,
upper panel) and the survival protein survivin (Pab, 1:1000; R&D Systems,
Abingdon, UK, lower panel). No difference in the cH2AX biomarker
expression between the two lines was detected. ZL55 SPT cells showed
higher basal survivin expression.
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epithelial to mesenchymal transition and chemoresistance (56) like
observed in our study. It would be interesting to further investigate the
potential of induction of differentiation as therapeutic option. In this
context, it is noteworthy that all-trans-retinoic acid treatment de-
creased growth of a sarcomatoid MPM cell line in vivo without in-
duction of apoptosis (57). Since WT1 is controlled by retinoic acid
(58), one possibility which remains unexplored is that WT1 was
induced and it led to tumor cell differentiation and growth arrest.
Taken together, our results support the hypothesis that MPM re-
currence develops from mesothelium precursor-like cells. But most
importantly, we rise for the first time an issue that is seldom taken into
account in mesothelioma biology: mesothelium has mesodermal
Fig. 4. SP cells are enriched in CD105/low cells with increased tumorigenicity (A) The DCVefflux assay was performed to identify SP cells as indicated in the legend
to Figure 1, followed by cell staining with an antibody against CD105 labeled with allophycocyanin (SN6) to identify CD105/low- and CD105high-expressing cells. The
SP fraction was then evaluated gating these two populations. (B) SDM103T2 cells were stained with anti-podoplanin and anti-CD105, then CD105/low and CD105high
cells were analyzed in an Forward Scatter Channel Area histogram (cell size, lower panel) revealing that CD105/low cells (blue) are smaller in cell size compared with
CD105high cells (red). Number above the cell size plot represents the cell size ratio of CD105/low to CD105high cells size (n 5 9). (C) CD105/low- and CD105high-
expressing ZL55 cells were sorted, mixed with Matrigel and injected under the renal capsula of 1 Gy-irradiated NOD/SCID mice. Tumor volume was assessed after 12
weeks. CD105/low cells induced significantly (P, 0.02) bigger tumors. (D) Increased proliferation in representative CD105/low- and CD105high-derived tumors was
buttressed by staining with a proliferation marker Ki67 antibody (B126.1, 1:50; Abcam). No primary antibody was added in controls. The scale bar represents 20 lm.
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origin and undergoes mesenchymal to epithelial transition during de-
velopment. Mesothelioma progression from epithelioid to biphasic to
sarcomatoid seems to follow a ‘backward to precursor’ epithelial to
mesenchymal transition, which for the moment has not been thor-
oughly addressed because of the complexity of mesothelium itself
which maintains some mesenchymal characteristics (e.g. vimentin
_expression). Using tools that are already largely used in the clinic
such as immunohistochemistry for WT1 and podoplanin, we provide
knowledge that could be easily implemented in large cohorts of
patients to verify whether it could predict time to relapse and allow
adaptation of patient follow-up.
Supplementary material
Supplementary Tables I and II and Figures 1–7 can be found at http://
carcin.oxfordjournals.org/
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